GCIIQ-AI deploys advanced imaging software at Insel Gruppe in Switzerland, shares jump
() , an investment company focused on medical imaging diagnostics, announced that its wholly-owned subsidiary Imaging Biometrics had successfully deployed its software at Insel Gruppe AG in Bern, Switzerland. Imaging Biometrics (IB) specialises in automated software solutions for quantitative analysis of MRI and CT exams.
The installation at Insel Gruppe was facilitated through Bayer's Calantic platform on which IB's exclusive algorithms are made available under a partnership agreement. The incorporation of IB's software into Insel's workflow should help the former standardise its imaging procedures with enhanced lesion detection and patient monitoring, ultimately leading to better patient outcomes.
Prof. Roland Wiest, MD, Deputy Director of Neuroradiology at Insel Gruppe, commented: "The adoption of IB's advanced imaging is expected to be a game-changer in our patient care strategy. We foresee an immediate enhancement in our ability to tailor treatments to individual needs."
View from Vox
A significant contract for IQ-AI's Imaging Biometrics as it deploys its full suite of applications at Insel Gruppe in Bern. Clinicians at Insel will benefit from IB's advanced quantitative imaging that offers significantly enhanced precision and reliability compared to older imaging methods. The technology will especially benefit neuroradiologists, oncologists, and surgeons, enabling them to make decisions more quickly.
For radiologists, the precise imaging that the platform affords means better and more efficient diagnostics and biomarker qualification, and in turn better treatment planning, decision-making and ultimately patient care. The contract win represents further validation of IB's software that should accelerate pipeline momentum and improve visibility. shares jumped 11% on the news.
Adding to today's announcement is a string of recent positive news from IB, including a Rare Pediatric Disease Designation grant by the US FDA for its lead drug candidate oral gallium maltolate (GaM). The candidate has demonstrated promising potential in pre-clinical and clinical settings for the treatment of multiple brain tumors. IB was also recently awarded $100k by Musella Foundation for development of the drug.
Follow News & Updates from IQ-AI:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.